AMBI Receives New Mineral Taste-Masking Patent.Business/Health Editors & Medical Writers PURCHASE, N.Y.--(BW HEALTHWIRE)--Dec. 12, 2000 Extensive Commercial Applications Possible for Proprietary Technology Which Masks Objectionable Taste and After-taste of Ingestible Minerals AMBI AMBI Associação Médica Brasileira Iridologia Inc. (Nasdaq:AMBI) today announced that it received US Patent No. 6,156,332 covering compositions and their uses for reducing the unpleasant taste and after-taste of a wide range of mineral supplements including potassium potassium (pətăs`ēəm), a metallic chemical element; symbol K [Lat. kalium=alkali]; at. no. 19; at. wt. 39.0983; m.p. 63.25°C;; b.p. 760°C;; sp. gr. .862 at 20°C;; valence +1. , calcium, zinc and magnesium. Gail Montgomery, AMBI's President and Chief Executive Officer, commented, "This new technology strengthens our ability to deliver mineral supplements in a form that promotes consumer acceptance and longer-term use. The unpleasant taste and after-taste associated with minerals has been a limiting factor A factor or condition that, either temporarily or permanently, impedes mission accomplishment. Illustrative examples are transportation network deficiencies, lack of in-place facilities, malpositioned forces or materiel, extreme climatic conditions, distance, transit or overflight rights, in the development of efficacious ef·fi·ca·cious adj. Producing or capable of producing a desired effect. See Synonyms at effective. [From Latin effic supplements, and in their use in food fortification Food fortification is the public health policy of adding Micronutrients (essential trace elements and vitamins) to foodstuffs to ensure that minimum dietary requirements are met. , over-the counter and prescription products. Our patented technology allows for the inclusion of minerals in a host of new and existing product applications. We now plan to pursue a development and licensing effort to bring the benefits of our discovery to the general public." AMBI noted that it had developed the taste-masking technology as part of a recent successful program to formulate a potassium supplement. This product is targeted for hypertensive hypertensive /hy·per·ten·sive/ (-ten´siv) 1. characterized by increased tension or pressure. 2. an agent that causes hypertension. 3. a person with hypertension. patients on diuretic diuretic (dī'yərĕt`ĭk), drug used to increase urine formation and output. Diuretics are prescribed for the treatment of edema (the accumulation of excess fluids in the tissues of the body), which is often the result of underlying medication who must replace potassium lost through the kidneys. The product is capable of delivering a prescription dose of potassium but without the metallic taste inherent in many existing products. Ms. Montgomery continued, "In working with the technology, it became apparent that the potential application is broader than the $0.4 billion U.S. wholesale market for prescription potassium supplementation. We intend to draw upon our strength in the fast-growing $1.3 billion mineral sector of the nutrition industry to maximize the opportunities associated with this technology." The taste masking mask·ing n. 1. The concealment or the screening of one sensory process or sensation by another. 2. An opaque covering used to camouflage the metal parts of a prosthesis. composition-of-matter and use patent is the 25th issued nutrition products patent in AMBI's portfolio. AMBI develops and markets proprietary nutrition products. This press release may contain certain forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. . The words "believe," "expect," "anticipate" and other similar expressions generally identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based largely on the company's current expectations and are subject to a number of risks and uncertainties, including without limitation: the effect of the expiration of patents; regulatory issues; uncertainty in the outcomes of clinical trials; changes in external market factors; changes in the company's business or growth strategy or an inability to execute its strategy due to changes in its industry or the economy generally; the emergence of new or growing competitors; various other competitive factors; and other risks and uncertainties indicated from time to time in the company's filings with the Securities and Exchange Commission, including its most recent Registration Statement on Form S-3, the Prospectus dated April 25, 2000, and its Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended June 30, 2000. Actual results could differ materially from the results referred to in the forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements contained in this press release will in fact occur. Additionally, the company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that may |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion